Search

everythinglearnresearchcommunity

for

Search:↓

Mindfulness-based cognitive therapy may reduce social anxiety and improve wellbeing in people with alopecia areata.

Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.

In Denmark from 1995 to 2016, hospital-treated alopecia areata cases increased, mostly affecting women and those over 50.

Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.

The Lexington LaserComb helped regrow hair in mice with a condition similar to human hair loss.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

The study found that immune responses disrupt hair growth cycles, causing hair loss in alopecia areata.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Both mouse and rat models are effective for testing alopecia areata treatments.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Latanoprost can effectively treat eyelash hair loss, with 45% of patients showing hair regrowth and no reported side effects.

Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.

Recognizing the different stages of alopecia areata is crucial for accurate diagnosis and treatment.

Apremilast was not effective in treating moderate-to-severe alopecia areata.